Gts Securities LLC Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Gts Securities LLC

  • $46.5 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$193.33 - $291.99 $3 Million - $4.53 Million
-15,500 Reduced 38.46%
24,800 $6.95 Million
Q1 2024

May 15, 2024
BUY
$171.37 - $283.23 $1.29 Million - $2.12 Million
7,500 Added 22.87%
40,300 $10.8 Million
Q4 2023

Feb 14, 2024
BUY
$120.4 - $237.13 $1.69 Million - $3.32 Million
14,000 Added 74.47%
32,800 $7.59 Million
Q3 2023

Nov 15, 2023
BUY
$146.04 - $225.78 $2.75 Million - $4.24 Million
18,800 New
18,800 $2.75 Million

Others Institutions Holding MDGL

# of Institutions
298
Shares Held
22M
Call Options Held
757K
Put Options Held
370K
View Full List

About MADRIGAL PHARMACEUTICALS, INC.

MDGL Quotes by TradingView
  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.63B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email